[SE] FragMAX screening of SARS CoV-2 nsp10-nsp14ExoN complex

To date, the SARS CoV-2 virus has infected >400 million people, causing ~6 million fatalities globally. Multiple research efforts are ongoing, aimed at different ways to target the virus, however there is still no magic bullet available. Current vaccines offer excellent protection against severe disease and death, but ever-emerging new variants could be better controlled with small molecule inhibitors that are not dependent on the spike protein structure. To this end we would like to access the FragMAX platform BioMAX to screen for fragment hits against key components of the SARS CoV-2 viral replication machinery, the nsp10-nsp14ExoN complex.